Lords Mark Secures Indias First Software Medical Device License for Biomescan

In August 2026, Lord’s Mark Industries secured India's first software medical device manufacturing license for its Biomescan Analytics Platform, which mainly analyzes gut microbes through bioinformatics to facilitate health risk insights and dietary advice, as interest in gut health and microbiome-based testing for wellness grows in India.

The Gut-Check Revolution

The human gut houses trillions of microorganisms that influence digestion, immunity, and metabolism. Research has connected the gut microbiome to conditions like diabetes, obesity, and cardiovascular diseases. Biomes can analyze an individual's microbiome by leveraging bioinformatics to facilitate insights into microbial diversity, metabolic functions, and dietary recommendations, although it is not a standalone clinical diagnosis.

Lord’s Mark Industries aims to establish 3,000 Health and Wellness Centres across India in collaboration with healthcare professionals, supporting preventive health practices. Their platform, Biomescan, combines whole metagenome sequencing with a bioinformatics pipeline to develop personalized microbiome profiles and nutritional advice.

Managing Director, Lord’s Mark Industries, Sachidanand Upadhyay also emphasized the shift from reactive treatment to proactive prevention, stating that the goal is to empower individuals with insights into their health before diseases develop. With the increasing burden of non-communicable diseases in India, Biomescan represents a new era where genomics and nutrition combine to develop truly personalized wellness by making preventive healthcare accessible, affordable, and impactful for millions non-communicable diseases in India.

Impact on Healthcare Industry

This license positively shifts the healthcare system from reactive treatment to proactive wellness by providing early risk assessment through gut microbiome profiling and addressing systemic care limitations like delayed diagnosis and generalized treatment models.

This initiative transforms healthcare by shifting the focus from treating late-stage symptoms to assessing early health risks through advanced microbial insights. It introduces personalized medicine through data-driven nutrition, expands nationwide wellness networks through medical partnerships, and sets a regulatory compliance milestone for Software as a Medical Device under Indian Medical Devices Rules.

Furthermore, it also addresses traditional industry limitations by replacing delayed interventions with early disease-susceptibility tracking and mitigates generic diets by mapping unique enterotypes. It also resolves diagnostic blind spots with bioinformatics and decentralizes health risk data through scalable software over heavy clinical infrastructure.

Impact on the Medical Device Services Industry

The global medical device services market size was calculated at USD 19.11 billion in 2025 and is predicted to increase from USD 20.55 billion in 2026 to approximately USD 39.21 billion by 2035, expanding at a CAGR of 7.45% from 2026 to 2035.

According to Precedence Research, this platform benefits the medical device services industry by shifting from traditional hardware to certified digital health diagnostics and paving the various ways for data-driven preventive wellness and bioinformatics integration.

The industry is mainly transforming through pioneering regulatory frameworks for AI-driven software tools, a strategic shift toward proactive early risk profiling, deep clinical ecosystem partnerships, and personalized nutrition growth linked to digital diagnostics and customized diets and targeted nutraceutical formulations. Meanwhile, the industry also addresses industry hurdles by eliminating hardware and manufacturing dependencies, establishing clear compliance through formal licensing, and dramatically lowering delivery costs through automated bioinformatics pipelines.

Impact on the Life Science Analytics Industry

The global life science analytics market size was calculated at USD 11.97 billion in 2025 and is predicted to reach around USD 26.63 billion by 2035, expanding at a CAGR of 8.32% from 2026 to 2035.

According to Precedence Research, this platform positively impacts the industry by transforming from reactive treatment to proactive wellness, connecting the gap between raw genomic data and mainstream clinical understanding, and targeting India's precious preventive healthcare.

This regulates the formal compliance benchmark for software-based medical tools under Indian regulatory frameworks, with mainstream integration shifting gut microbiome and bioinformatics analysis out of experimental research. Personalized nutrition, lifestyle interventions, and specialized health formulations for adoption and accessibility. Replacing reactive symptom checks with early risk indicators, and blending digital software scaling with physical wellness networks, helps digital health innovators overcome regulatory ambiguity, reactive bias, and accessibility limitations with clear licensing paths.

About Lord’s Mark Industries Limited

Lord’s Mark Industries Limited is a diversified Indian conglomerate operating across healthcare, diagnostics, renewable energy, and the technology sector, founded in 1998 and headquartered in Mumbai. The company offers diagnostics and medTech, contactless remote patient monitoring and AI-based early warning systems, as well as surgical and biotechnology support and pain relief items. The company’s main goal is to build self-sustaining businesses of national importance, transforming proactive prevention by expanding green energy access to deliver long-term value to stakeholders globally.